Avoidance of cardiac toxicity during the application of immune checkpoint inhibitors: a safety systematic review combining network meta-analysis and pharmacovigilance study. (PubMed, Front Immunol) - Sep 16, 2026 - "Disproportionality analysis revealed that both PD-1 and PD-L1 inhibitors carry risks of myocarditis, and the combination of bevacizumab, relatlimab, and ipilimumab may cause increased cardiac toxicity...PD-1 (nivolumab, pembrolizumab) and PD-L1 (atezolizumab, avelumab) agents present a higher risk of myocarditis and acute myocardial infarction. Moreover, combination regimens involving PD-1/PD-L1 further elevate the risk of cardiac toxicity, underscoring the necessity for vigilant monitoring in patients with underlying heart disease. https://www.crd.york.ac.uk/PROSPERO/, identifier CRD420261357478."
Adverse events • Checkpoint inhibition • Clinical • Journal • Retrospective data • Review • Cardiovascular • Heart Failure • Myocardial Infarction • Oncology • Ventricular Tachycardia • CTLA4
|
|
Han Chen; Hanfang Xu; Keer Xuan; Qingchun Zhao; Tianshu Ren; Yongqi Shan
|